Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK ...

Tom Nolan reviews this week’s research You never have to wait too long for a trial of a new drug for migraine. The latest one is Lu AG09222, a monoclonal antibody to pituitary adenylate ...

The humanized monoclonal antibody directed against the pituitary adenylate cyclase-activating polypeptide ligand, Lu AG09222, is better than placebo.

Pituitary adenylate cyclase-activating polypeptide signalling has been linked to migraine pathogenesis. In this Review, Ashina and co-workers explore the molecular and cellular mechanisms of ...

The migraine market across the 7MM is poised to grow at a compound annual growth rate (CAGR) of 6.0% from $9.2bn in 2023 to ...

For this purpose, the researchers conducted a Phase 2, double-blind, randomized, placebo-controlled trial involving adult ...

A potential mediator of migraine pathogenesis is the signaling molecule pituitary adenylate cyclase–activating polypeptide (PACAP). 5 Experimental studies have shown that intravenous infusion of ...

The authors further identify adenylate cyclase 1/8, cAMP, and PKA as the crucial mitigators of these actions. While some comments have been identified below, the experiments presented are thorough and ...

One of the biochemical systems that produces ATP is the essential enzyme adenylate kinase, which catalyzes the production of ATP from the building blocks ADP and AMP. The enzyme is dependent on ...

The researchers tested their method on the protein adenylate kinase and found that its predicted movements matched experimental data. They also successfully predicted the functional movements of ...